Incident Atrial Fibrillation Following Anthracycline-Based Adjuvant Chemotherapy in Women with Breast Cancer: A Single-Centre Retrospective Cohort Study.
- 1Baskent University Hospital, Istanbul 34662, Türkiye.
Abstract
Background/Objectives: Anthracyclines carry considerable cardiotoxicity risk, and atrial fibrillation (AF) during cancer treatment adversely affects morbidity and mortality. We compared the incidence of clinically documented AF and explored its early clinical correlates between anthracycline-containing and non-anthracycline adjuvant regimens in triple-negative breast cancer (TNBC). Methods: This single-centre retrospective cohort included consecutive women with stage II TNBC treated with breast-conserving surgery and adjuvant doxorubicin-cyclophosphamide followed by docetaxel (AC-T) or docetaxel-cyclophosphamide (TC) between 2018 and 2023. ECG and echocardiography were performed at baseline, month one, and month six. Clinically documented AF was defined as AF documented on a scheduled or symptom-triggered 12-lead ECG or as AF lasting ≥30 s on symptom-triggered 72 h Holter monitoring. Patients with structural or coronary heart disease, complete bundle branch block, or non-sinus rhythm were excluded. Results: Among 140 women (mean age, 64 ± 12 years; 64 AC-T), 17 (12.1%) developed clinically documented AF within six months. AF was more frequent with AC-T (18.8% vs. 6.6%; absolute risk difference, 12.2% [95% CI, 1.1-23.3%]; risk ratio, 2.85 [1.07-7.58]; log-rank p = 0.030), and the association persisted after inverse probability of treatment weighting (OR, 3.28 [1.05-10.24]). At one month, PR prolongation > 20 ms was associated with incident AF (OR, 5.16 [1.79-14.89]), whereas conventional echocardiographic changes did not differ between regimens. Conclusions: The AC-T regimen was associated with more clinically documented incident AF than TC. Early PR prolongation, occurring without detectable changes in conventional echocardiographic parameters, may be an informative early electrical signal of AF risk, although prospective validation is required.
Related
- Assessment of myocardial injury following anthracycline chemotherapy in children with leukemia by echocardiography
- Predictive Value of P-Wave Dispersion Combined with Left Atrial Reservoir Strain for Incident Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.
- Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
- Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study
- Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS).
BibTeX
@article{arslan2026incident,
title = {{Incident Atrial Fibrillation Following Anthracycline-Based Adjuvant Chemotherapy in Women with Breast Cancer: A Single-Centre Retrospective Cohort Study.}},
author = {Abdulla Arslan and Özgür Çağaç and Fatih Beşiroğlu and Burak Hünük},
journal = {Biomedicines},
year = {2026},
month = sep,
doi = {10.3390/biomedicines14102214},
url = {https://europepmc.org/article/MED/42940021},
note = {CC BY},
}
RIS
TY - JOUR
TI - Incident Atrial Fibrillation Following Anthracycline-Based Adjuvant Chemotherapy in Women with Breast Cancer: A Single-Centre Retrospective Cohort Study.
AU - Abdulla Arslan
AU - Özgür Çağaç
AU - Fatih Beşiroğlu
AU - Burak Hünük
PY - 2026
DA - 2026/09/30
JO - Biomedicines
DO - 10.3390/biomedicines14102214
UR - https://europepmc.org/article/MED/42940021
AB - Background/Objectives: Anthracyclines carry considerable cardiotoxicity risk, and atrial fibrillation (AF) during cancer treatment adversely affects morbidity and mortality. We compared the incidence of clinically documented AF and explored its early clinical correlates between anthracycline-containing and non-anthracycline adjuvant regimens in triple-negative breast cancer (TNBC). Methods: This single-centre retrospective cohort included consecutive women with stage II TNBC treated with breast-conserving surgery and adjuvant doxorubicin-cyclophosphamide followed by docetaxel (AC-T) or docetaxel-cyclophosphamide (TC) between 2018 and 2023. ECG and echocardiography were performed at baseline, month one, and month six. Clinically documented AF was defined as AF documented on a scheduled or symptom-triggered 12-lead ECG or as AF lasting ≥30 s on symptom-triggered 72 h Holter monitoring. Patients with structural or coronary heart disease, complete bundle branch block, or non-sinus rhythm were excluded. Results: Among 140 women (mean age, 64 ± 12 years; 64 AC-T), 17 (12.1%) developed clinically documented AF within six months. AF was more frequent with AC-T (18.8% vs. 6.6%; absolute risk difference, 12.2% [95% CI, 1.1-23.3%]; risk ratio, 2.85 [1.07-7.58]; log-rank p = 0.030), and the association persisted after inverse probability of treatment weighting (OR, 3.28 [1.05-10.24]). At one month, PR prolongation > 20 ms was associated with incident AF (OR, 5.16 [1.79-14.89]), whereas conventional echocardiographic changes did not differ between regimens. Conclusions: The AC-T regimen was associated with more clinically documented incident AF than TC. Early PR prolongation, occurring without detectable changes in conventional echocardiographic parameters, may be an informative early electrical signal of AF risk, although prospective validation is required.
SN - 2227-9059
ER -